Ask a clinician about treatment after osteoporosis or a fragility fracture; calcium alone does not replace prescribed therapy

Cost: Treatment requires a prescription and can continue for years. The source describes weekly oral medicines and annual infusions among the options, and bone-density reassessment annually at first, then every one to two years when stable. These are source descriptions, not a personalized regimen; the clinician determines treatment and monitoring.

In plain language: In the populations studied, some osteoporosis treatments reduced hip and spinal fractures. A trial after surgically treated hip fracture reported fewer subsequent fractures with annual treatment. Calcium supplements alone are not a substitute for indicated prescription treatment.

Indications and findings reported by the source: Fragility fractures occur after minor trauma or ordinary activity. The Chinese Medical Association's 2017 guideline describes three treatment categories: previous spinal or hip fragility fracture; bone-density T-score at or below -2.5 regardless of fracture history; and low bone mass with a wrist, upper-arm or pelvic fragility fracture or high calculated fracture risk. It states that sufficient evidence does not support replacing other osteoporosis medicines with calcium alone. A 2025 Cochrane alendronate review reported, in postmenopausal women with osteoporosis or fractures, hip-fracture RR 0.49 (95% CI 0.25–0.96) and symptomatic vertebral-fracture RR 0.45 (0.28–0.73).

HORIZON enrolled 2,127 people after hip-fracture surgery, mean age 74.5. Annual zoledronic acid began within 90 days of surgery; median follow-up was 1.9 years. New fractures occurred in 8.6% versus 13.9%, around 35% fewer, and deaths in 9.6% versus 13.3%, around 28% fewer in that trial. The cited guideline describes around 20% mortality from complications within a year after hip fracture. A Chinese national survey in 2017–2018 found treatment use in only 1.4% of women and 0.3% of men with diagnosed osteoporosis or fracture history.

Source author's evidence grade: A; not site verification or professional approval.

Notes and dispute: A meta-analysis of 38 trials did not establish lower overall mortality for osteoporosis drugs (RR 0.98, 95% CI 0.91–1.05), nor for zoledronic acid alone (RR 0.88, 0.68–1.13); its authors concluded these medicines should be used to prevent fractures. The cited Cochrane fracture findings were rated low to moderate certainty. In women without previous fracture and at lower fracture risk, alendronate did not show a clear hip-fracture benefit (RR 0.76, 0.43–1.32). Trials lasting a few years cannot fully characterize rare harms such as jaw osteonecrosis or atypical femoral fractures. Keep follow-up appointments and do not change or stop medicines independently. Choice of oral or injected treatment belongs to the clinician. See entry 39 for bone-density assessment. Menopausal hormone therapy can also reduce fractures but is generally considered here when alternatives are unsuitable; for treating hot flushes and night sweats, see chapter 2, entry 43. The source considers benefits for the reader and their parents.

Original source bibliography (titles retained as supplied): 中华医学会骨质疏松和骨矿盐疾病分会 (2017). 原发性骨质疏松症诊疗指南(2017). 中华骨质疏松和骨矿盐疾病杂志, 10(5), 413-443（表 10 抗骨质疏松症药物治疗适应证；钙剂一节；疗效监测一节）. https://html.rhhz.net/GUSS/html/cc825127-29a3-47c1-9a95-7a212fdcce55.htm ; Wells GA, Hsieh SC, Peterson J, et al. (2025). Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001155.pub3 ; Lyles KW, Colón-Emeric CS, Magaziner JS, et al. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa074941 ; Cummings SR, Lui LY, Eastell R, Allen IE (2019). Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.2779 ; Kahwati LC, Kistler CE, Booth G, et al. (2025). Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force. JAMA. https://doi.org/10.1001/jama.2024.21653 ; Wang L, Yu W, Yin X, et al. (2021). Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.21106